A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) /… (NCT02309671) | Clinical Trial Compass
CompletedPhase 2
A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment
Japan159 participantsStarted 2014-12
Plain-language summary
This trial investigates the effects of several doses of FE 999049 in Japanese women undergoing IVF/ICSI treatment.
Who can participate
Age range20 Years – 39 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Women diagnosed with tubal infertility, unexplained infertility, infertility related to endometriosis stage I/II or with partners diagnosed with male factor infertility
* Women eligible for IVF and/or ICSI treatment
* Women aged 20-39 years
* Women with body mass index (BMI) of 17.5-32.0 kg/m2
Exclusion Criteria:
* Women with polycystic ovary syndrome (PCOS) associated with anovulation, endometriosis stage III/IV
* Women with history of recurrent miscarriage
* Women with contraindications to controlled ovarian stimulation with gonadotropins
* Women with three or more controlled ovarian stimulation cycles
What they're measuring
1
Number of oocytes retrieved
Timeframe: End of stimulation (max 16 days after investigational medicinal product (IMP) start)